Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 35Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 26Neoplasms 16Uterine Cervical Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Sarcoma 9Rectal Neoplasms 9Carcinoma, Renal Cell 9Carcinoma, Hepatocellular 9Prostatic Neoplasms 8Neoplasm Metastasis 8Lymphoma 8Brain Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Oropharyngeal Neoplasms 7Multiple Myeloma 7Melanoma 7Head and Neck Neoplasms 7Glioblastoma 7Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Thyroid Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Colonic Neoplasms 6Salivary Gland Neoplasms 5Ovarian Neoplasms 5

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Lung Neuroendocrine Tumor × Fluorodeoxyglucose F18 × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡